Drug Trial Radar · NCT03687333
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment
Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Dec 4, 2018
Primary completion
Dec 30, 2020
Study completion Dec 30, 2020
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 months, up to 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate effect of 52-week treatment with Alglucosidase Alfa in the extension of survival and improvement of cardiomyopathy measured by Left Ventricular Mass Index in Chinese patients with infantile-onset Pompe Disease. Secondary Objectives: * To observe the improvement of physical growth, motor and cognitive development of 52-week treatment with Alglucosidase Alfa in infantile-onset Pompe Disease from the baseline. * To observe the efficacy on survival free of invasive ventilation, use of any ventilation support of 52- week treatment with Alglucosidase Alfa in Chinese patients with infantile-onset Pompe Disease. * To evaluate the safety and tolerability of Alglucosidase Alfa in Chinese patients with infantile-onset Pompe Disease.
Conditions
- Glycogen Storage Disease Type II
Interventions
ALGLUCOSIDASE ALFA (MYOZYME)Drug
Pharmaceutical form: cake or powder for injection Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: at week 52
- Left Ventricular Mass Index (LVMI)Time frame: at week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site number
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.